## **Public Health Link**

From the Chief Medical Officer for Wales

Distribution: As Appendix 1

**From:** Dr Frank Atherton, Chief Medical Officer for Wales

Date: 29 January 2021

Reference: CEM/CMO/2021/5

**Category:** Immediate (cascade within 24 hours)

**Title**: Covid-19 Therapeutic Alert - Antimicrobials (Azithromycin And Doxycycline) Not

Beneficial In The Management Of Covid-19 (Sars-Cov-2) Positive Patients

## Dear colleagues,

The recent announcement from the National Institute for Health Research (NIHR) supported PRINCIPLE trial demonstrates the vital importance of robust clinical trials in our response to COVID-19. The lack of beneficial effect in patients aged over 50 who are treated with either azithromycin or doxycycline at home in the early stages of COVID-19 suggests that these antibiotics should not be used within primary care for the treatment of COVID-19 unless there is an additional licensed indication. Overuse of antibiotics in the community can contribute to antimicrobial resistance.

Yours sincerely

DR FRANK ATHERTON

## To: NHS Wales Shared Services Partnership to forward to:

All General Practitioners

To: Health Boards and NHS Trusts:

Chief Executives

Medical Directors for onward distribution to:

**Hospital Doctors** 

**Nurse Directors** 

**Directors of Public Health** 

Cc: Public Health Wales:

Chief Executive

Director of Public Health Services

Consultants in Communicable Disease Control

Microbiologists

Consultant Epidemiologists

Vaccine Preventable Disease Programme

Cc: NHS Direct Wales

**British Medical Association** 

Royal College of GPs

Royal College of Physicians

Academy of Medical Royal Colleges

Royal College of Nursing Royal College of Midwives

Royal College of Paediatrics and Child Health Wales